Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. by Detre, SI et al.
 1 
Immunohistochemical phenotype of breast cancer during 25-
year follow-up of the Royal Marsden Tamoxifen Prevention 
Trial  
Simone I Detre1, Susan Ashley2, Kabir Mohammed2, Ian E Smith3, Trevor J 
Powles4 and Mitch Dowsett1 
 
Correspondence to:  Professor Mitch Dowsett, Academic Department of 
Biochemistry, 4th Floor Wallace Wing, Royal Marsden Hospital NHS Trust, 
Fulham Road, London SW3 6JJ 
E-mail: mitch.dowsett@icr.ac.uk 
 
1 Academic Department of Biochemistry, 4th Floor Wallace Wing, Royal 
Marsden Hospital NHS Trust, Fulham Road, London, SW3 6JJ 
 
2 RDSU – Research and Development, Royal Marsden Hospital NHS 
Trust, Sutton, SM2 5PT 
 
3 Breast Unit, Royal Marsden Hospital NHS Trust, Fulham Road, 
London, SW3 6JJ 
 
4 Cancer Centre London, Wimbledon, London, SW19 5NB 
 
 
Funding: 
All authors received funding from the Da Costa International Fund for Breast 
Cancer Prevention Foundation and the Royal Marsden Hospital NIHR 
Biomedical Research Centre.  
 
Running title:  
Breast cancer phenotype and tamoxifen prevention  
 
Conflicts of interest: 
 
MD is a paid member of the Radius Scientific Board 
 
Article type: Research Article 
Word count: 2991 including abstract 
4 tables, 1 supplementary table, 1 figure  
  
 2 
 
Abstract  
The randomized double-blinded Royal Marsden Tamoxifen Breast Cancer 
Prevention Trial in healthy high-risk women started in 1986 and is still blinded. 
2471 eligible participants were randomly assigned to tamoxifen (20mg/day) or 
placebo for 8 years.  Analysis in 2006 showed a 30% risk reduction of ER-
positive invasive breast cancer mostly in the post treatment period. Biomarker 
analysis in this population may identify any sub-group specific preventive 
effects tamoxifen. After a median follow-up of 18.4 years, 242 patients had 
developed invasive cancer, 134 on placebo and 108 on tamoxifen.  From 
these, 180 tissue blocks were available and ER, PgR, Ki67, HER2 and EGFR 
were immunohistochemically analysed. A 32% reduction in ER+ and PgR+ 
invasive cancers resulted after 8 years of treatment. Quantitative levels of ER 
and PgR were lower in the tamoxifen-treated group, significantly so for ER 
(p=0.001).  These lower ER levels were restricted to the post-treatment period 
(p=0.018). Amongst the ER+ group there was a similar proportional decrease 
in PgR+ and PgR- tumours by tamoxifen. The median levels of Ki67 were 
similar in both arms. The numbers of HER2 positive and EGFR positive 
cancers were higher in the tamoxifen arm but not significantly so. In 
conclusion, tamoxifen’s preventive effects result in reduced ER-positive but 
not ER-negative tumours and reduced ER expression in the ER-positive cases 
largely confined to the post-treatment period. Overall reductions in PgR 
expression are explained by lower frequency of ER-positive cases. Impact on 
Ki67, HER2 and EGFR was modest. 
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Introduction 
In vivo laboratory evidence that the incidence of breast cancer could be 
reduced and an observed reduction in the risk of new contralateral breast 
cancer resulting from adjuvant treatment of women with primary breast cancer 
with the selective estrogen receptor modulator (SERM), tamoxifen(1, 2) 
indicated that this drug could be used to prevent breast cancer in healthy 
women. The first trial, the Royal Marsden Prevention Trial (RMPT), began 
recruitment in 1986(3). Three other major randomised, placebo-controlled 
trials of tamoxifen given for between 5 and 8 years were conducted.  Together 
with the RMPT these recruited a total of over 25,000 healthy women at 
increased risk of breast cancer. Overview of these trials confirmed a 
significant reduction in the risk of developing breast cancer of 33% that, 
among invasive tumours, was restricted to a reduction in the incidence of ER-
positive disease (by 44%)(4).   A reduction in risk persisted for at least 15 
years(4, 5).    These positive data alongside the low incidence of side effects 
with tamoxifen have led to it being recommended for use by regulatory bodies 
as a risk-reduction strategy in healthy women at increased risk of breast 
cancer. 
 The phenotype of primary breast tumors is a major determinant of the 
medical treatment of patients and certain key features are associated with 
long-term prognosis. ER and HER2 are assessed in all tumours for treatment 
selection and progesterone receptor (PgR) and the proliferation marker Ki67 in 
most for the assessment of prognosis. Information on these biomarkers in 
patients developing breast cancer either during or after risk reduction therapy 
with tamoxifen is therefore important for better understanding of the likely 
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benefits of such treatment as well as for the identification of any sub-group 
specific preventive effects. Other than ER status there have been few reports 
on any differences in the phenotype of breast cancers developing during or 
after the tamoxifen treatment period. We previously reported that in 67 tumors 
from the RMPT (35 placebo, 32 tamoxifen arm) median ER levels were lower 
in the tumours developing in tamoxifen-treated patients(6).    At that time when 
most patients were still on their randomized treatment (median follow-up 70 
months) there was no reduction in breast cancer incidence.  
The most recent report of the clinical outcome of the trial was at a median 
of 13 years 2 months (maximum 19 years 10months)(5).   After that length of 
follow-up 186 patients had developed invasive cancer (104 placebo, 82 
tamoxifen; hazard ratio [HR] 0.78 p=0.10) and 139 of these were ER-positive 
(86 placebo; 53 tamoxifen; HR 0.61, p=0.005). The HRs for the 8-year 
treatment period and the post-treatment period were 0.77 (p=0.3) and 0.48 
(p=0.004), respectively.  
In the meantime the NSABP have reported(7) the microarray gene 
expression analysis of 108 tumours from their P1 tamoxifen prevention trial, 
69 placebo and 39 tamoxifen-treated. ER expression, whether measured by 
semi-quantitative immunohistochemistry or gene expression, was lower in the 
27 ER-positive tumors on tamoxifen than those in the 57 ER-positive tumours 
in the placebo group. The only other gene to show substantial differential 
expression was GFRA1, which codes for the Glial cell line-derived 
neurotrophic receptor alpha-1 also known as Glial cell line-derived 
neurotrophic factor receptor (GDNFR). Our group has reported that activation 
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of this receptor in ER-positive breast cancer is associated with resistance to 
tamoxifen and aromatase inhibitors(8).   
The primary objective of the current study was to determine whether 
randomisation to possible risk-reduction treatment with tamoxifen or placebo 
was associated with differences in the commonly measured phenotypic 
markers ER, PgR, HER2 and Ki67 as well as epidermal growth factor receptor 
(EGFR). The last of these is uncommonly expressed in ER-positive tumours 
and is associated with tamoxifen resistance when it is(9).    The study was 
conducted in tumors from the RMPT which at its most recent analysis had 
completed over 20 years of follow-up(5) and gave us the opportunity to fulfill a 
secondary objective, i.e. to determine whether any phenotypic differences 
varied according to whether the patients were in the on-treatment or post-
treatment period at the time of tumor presentation.  
 
Materials and Methods 
The trial (I SRCTN07027313) was approved by the Royal Marsden 
Hospital Ethics Committee. Consent to use tissue for research was provided 
by all patients in whom tumours arose after 1st September 2006 when the 
Human Tissue Act became active. The study design and clinical outcome data 
have previously been published(5).   A total of 2494 healthy women were 
randomly assigned to oral tamoxifen (20mg/day) or placebo for a treatment 
period of 8 years. Participants, medical professionals and laboratory staff 
remain blind to the randomised treatment unless unblinding was specifically 
requested and the analyses are based on an intention to treat. 
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Immunohistochemical analyses for ER, PgR, Ki67, HER2 and EGFR were 
undertaken on sections from formalin-fixed paraffin wax-embedded blocks 
using reagents listed in Supplementary Table 1. The immunohistochemical 
staining was performed on a Dako Autostainer using REAL kits for all 
biomarkers except HER2. FISH analyses (PathVysion) were carried out on 
HER2 positive cases when scored as IHC2+. Haematoxylin & eosin stained 
slides were used to confirm presence of invasive breast carcinoma. In situ 
breast cancers were excluded. If patients received neoadjuvant therapy, core-
cut biopsies taken at diagnosis were used; otherwise sections from the 
excision biopsy were taken. 
ER and PgR were scored as H-scores (range 0-300)(10).  The positivity 
cut-off for ER and for PgR H-score was >1 to equate closely to that 
recommended in ASCO/CAP guidelines(11).    Ki67 was assessed as % 
positivity of nuclear stained cells and had no designated cut-off.  EGFR was 
scored as percentage positive membrane staining and deemed positive if the 
score was greater than 1. HER-2 was considered positive if the IHC score was 
assessed as 3+ by ASCO/CAP criteria, (12) or if assessed as 2+ and FISH 
analysis showed HER2/CEP17 ratio of >2.0. 
All analyses were carried out blind to randomisation with the trial 
statistician supplying pathology numbers and case details. All statistical 
analyses were performed by the trial statistician. The cut-off point for the 
current analysis was 1st October 2010. The primary endpoint was the 
occurrence of invasive breast cancer. Invasive breast cancer-free survival was 
calculated using the Kaplan Meier method. Non-invasive breast cancers were 
censored. The Cox proportional hazards model was used to check for the 
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treatment effect and hazard ratio with 95% confidence interval reported.  A 
secondary planned analysis of ER-positive invasive breast cancer was also 
done. Biomarker data were summarised and compared between treatment 
arms in the overall patient population and in subgroups according to ER-status 
and diagnosis of cancer during treatment or post-treatment.  The continuous 
biomarker variables were summarised using mean and 95% confidence 
interval and median and interquartile range.  The scores were then compared 
using the non-parametric Mann-Whitney U-test.  Categorical variables were 
summarised using number of observations and percentages according to 
treatment arms and compared using Chi-square test. 
 
Results 
The current IHC analysis was conducted in all available tumours that arose 
by 1st October 2010 (median follow-up 18.4 years, maximum 23.7 years). By 
that time 242 patients had developed invasive cancer, 134 on placebo and 
108 on tamoxifen (hazard ratio [HR] 0.80 95% CI 0.62-1.02, p=0.076) (Table 
1).  Of these 187 were ER-positive, 108 on placebo and 79 on tamoxifen (HR 
0.72 95%CI 0.54-0.97, p=0.028). The HR in the post-treatment period for all 
patients was 0.74 (95%CI 0.53-1.02, p=0.067) and for ER-positive cases was 
0.68 (95% CI 0.47- 0.996, p=0.048). A complete updated clinical report of the 
trial will be published separately. The efficacy end-points included in this 
report are sufficient to allow full interpretation of the tumor-based biomarker 
data. 
Immunohistochemical (IHC) data was available from 179 patients. 
Reasons for non-availability of data were: 38 tumour blocks could not be 
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retrieved from sites; 12 subjects either had no written consent for biomarker 
analysis recorded or declined; 11 samples had too little tumour to assess 
biomarkers.  A similar proportion of tumours were available in the IHC cohort 
for each of the two arms: placebo, 75% (100/134); tamoxifen 73% (79/108).  
The major demographics of the population are shown in Table 2. In the 
tamoxifen arm in the IHC cohort there were 54 ER-positive and 25 ER-
negative tumours [1 ER-negative/PgR-positive]) compared with 86 ER-
positive, 14 ER-negative in the placebo arm.  The difference in the proportions 
of ER-positive and ER-negative tumours between the arms was statistically 
significant (chi-squared p=0.008).  
In the overall follow-up period PgR-positive status was also lower in the 
tamoxifen arm than in the placebo arm (63% vs 76%, p=0.06) (Table 3). This 
was only statistically significant beyond 8 years (p=0.039) but the proportions 
were little different from those in the first 8 years (Table 4). Overall 76 (76%) 
tumours were ER-positive/PgR-positive in the placebo arm compared with 49 
(62%) in the tamoxifen arm. 
As in the earlier 13-year median follow-up clinical report (6) there was a 
greater preventive effect of tamoxifen in the post-treatment period in this IHC 
cohort (0-8 years: 40 tamoxifen, 44 placebo; beyond 8 years: 39 tamoxifen, 56 
placebo) (Table 3). There was no significant difference in the proportions of 
ER-positive versus ER-negative tumours between the treatment arms in the 
first 8 years but only 64% were ER-positive in the tamoxifen arm after 8 years 
compared with 86% in the placebo arm (p=0.014). 
Among the ER-positive tumours the ER level as estimated by H-score was 
somewhat lower in tamoxifen-treated tumours but this was not statistically 
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significant either overall (p=0.053) or in the separate time periods (Tables 3 
and 4). PgR levels also showed non-significant trends to being lower in the 
ER-positive cases.  
There were 12 HER2-positive cases in the tamoxifen arm and 10 in the 
placebo. Fifteen cases were EGFR positive in the tamoxifen arm and 12 in the 
placebo arm (Table 3; p=NS for HER2 and EGFR). 
The median level of Ki67 was 10.2% in both the tamoxifen and placebo 
arms overall and was also little different between the arms in the two time 
periods (Tables 3 and 4). The mean levels were, however, higher among the 
tamoxifen treated patients indicating a skewed distribution that was particularly 
apparent in the post-8 year period. These higher values of Ki67 in the overall 
time period are apparent in both the ER-positive and ER-negative treated 
groups (Figure 1).  
 
Discussion 
Tamoxifen was the first SERM to be shown to be effective at breast cancer 
risk reduction in healthy women. The benefit-harm ratio is sufficiently 
favourable for its use to be approved by regulatory agencies in defined high-
risk groups in Europe and the USA.  This position has been established as a 
result of 4 large randomized trials, including the RMPT reported here(13-15).    
The RMPT results on breast cancer incidence are largely consistent with 
those in the other trials although the reduced incidence of invasive breast 
cancer did not emerge until later than in other trials. This may be partly a 
matter of chance or may be affected by the greater familial risk for the RMPT 
population than that of the other trials with possible differences in the 
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phenotypical profile of the familial cancers(5, 6).   There is, therefore, interest 
in important phenotypic features of the tumours presenting in the RMPT trial 
on or after their preventive treatment, such as ER, PgR, HER2 and Ki67.   
 To provide maximum statistical power for the analyses we collected and 
analysed as many invasive breast cancers that occurred prior to 2010 in the 
trial as possible. The data therefore provide an update on breast cancer 
incidence beyond the most recent full publication of the trial(5) and from the 
most recent overview analysis(4).    As expected the data are no different for 
the first 8 years of follow-up during which treatment was given. But with the 
longer follow up the total number of invasive breast cancers increased from 
186 to 242, for the most part after 8 years post-randomisation.  The 
significantly reduced incidence of invasive breast cancer after tamoxifen 
treatment occurred exclusively in ER-positive disease. 
 Nearly three-quarters of the 242 breast cancers were collected and had 
sufficient tissue for analysis.  While the absence of the whole cohort may lead 
to some bias, the proportions of patients with tumours available for IHC were 
very similar in each of the two arms such that the conclusions from the cohort 
are likely to be representative of the whole trial.   
Given that it is estimated that many years are required for a breast 
carcinoma to develop from an initiation event to clinical presentation, 
reductions in breast cancer incidence in the first few years of prophylactic 
tamoxifen are likely to be due predominantly to an impact on pre-existing 
occult disease(16).    However, it seems likely that the majority of invasive 
breast cancers presenting in the post-8 year period in this trial would be due to 
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a primary preventive mechanism on either initiation or early promotional 
events.  
Tamoxifen is known to impact on PgR and Ki67 expression in established 
ER-positive breast cancer(17, 18).    In our studies of neoadjuvant use of 
tamoxifen the early increase seen in PgR after a few weeks of tamoxifen due 
to an early agonist effect of tamoxifen fell back to levels that are no different to 
the overall population after 12 weeks. Ki67 levels on the other hand were 
initially suppressed and remained suppressed. The observations on 
phenotype for tumours that present during treatment may therefore be 
affected by regulatory effects of treatment rather than being representative of 
the intrinsic tumour phenotype. In contrast in the post 8-year period of follow-
up any differences would be expected to be representative of the intrinsic 
phenotype of cancers that survived initiation or promotion during treatment or 
were initiated post treatment   
The major findings in this study are that the reduction in the incidence of 
breast cancer continues to be only in ER-positive disease even beyond 8 
years and those ER-positive tumours tend to also have lower ER levels than 
that in the placebo population. These effects are similar to those reported by 
Kim et al(7) although in that paper the data were from women having received 
a median of only 4.5 years of randomised therapy(15).    Our findings provide 
evidence against ER -negative cancers arising from ER positive precursors 
because by now we should be seeing a reduction in ER negative cancers. In 
fact there appears to be a consistent increase in ER negative cancers in the 
tamoxifen trials(4) including in this study. We and others have observed that 
breast cancer patients with ER-positive primary breast cancers that relapse on 
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tamoxifen therapy in a minority of cases exhibit ER-negative recurrences(19).    
Thus at least some of these ER-negative tumours in the treated women in 
RMPT may have presented as ER-positive disease if they had not been 
treated with tamoxifen. A substantial switch of ER-positive to ER-negative 
status in a subclinical tumour under the influence of tamoxifen could mask any 
preventive effect of tamoxifen on ER-negative subclinical tumours in this and 
other tamoxifen prevention studies(20).   The lower frequency of PgR-positive 
disease in the tamoxifen arm appears to relate largely to the reduced 
incidence of ER-positive disease.  
Ki67 is a frequently used marker of proliferation and is associated with 
poorer prognosis in breast cancer overall and in patients with ER-positive 
disease treated with endocrine therapy(21).    The median levels of Ki67 did 
not differ between the cancers in the tamoxifen and placebo arms in RMPT 
but there was an excess of patients with particularly high levels in the 
tamoxifen treated patients.  Given that Ki67 is well known to be more highly 
expressed in ER-negative tumours the excess of such tumours contributed to 
but did not appear to be completely responsible for the higher Ki67 levels.  
The incidence of HER2-positivity and EGFR-positivity both of which are 
features of poor prognosis disease was numerically higher in the cancers in 
the tamoxifen-arm but the differences did not approach statistical significance. 
 In summary, in the RMPT trial with prolonged follow-up there was an 
overall decrease in breast cancer incidence. The marked decrease in the 
incidence of ER-positive disease was partly offset by an increase in ER-
negative disease. Decreased PgR and increased Ki67 levels in the cancers in 
the tamoxifen arm were explained by the greater numbers of ER-negative 
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cancers.  The minor increases in Ki67, HER2 and EGFR and decreases in ER 
and PgR proximity are each generally associated with poorer outcome in 
primary disease presenting in the absence of endocrine therapy, but these 
differences were relatively minor and the majority of breast cancers that 
developed during or in the decade after tamoxifen preventive therapy 
presented as ER-positive/PgR-positive disease. 
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Legend to Figure: 
 
Figure 1: Expression of Ki67 according to treatment arm and ER status 
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Table 1: 
 
Summary of invasive breast cancer occurrence in tamoxifen and placebo arms 
in the BCPT by 1st Oct 2010 for all and ER+ patients during and after the 
treatment period. A: complete trial population; B: the IHC subset. 
 
A 
 
Invasive cancers HR (95% CI) Cox (p-value) 
All patients   
Overall follow-up (events: n=242) 
Placebo (n=134) 
Tamoxifen (n=108) 
 
1 
0.80 (0.62 – 1.02) 
 
0.076 
During treatment period (events: n=93) 
Placebo (n=49) 
Tamoxifen (n=44) 
 
1 
0.89 (0.60 – 1.34) 
 
0.589 
Post treatment period (events: n=149) 
Placebo (n=85) 
Tamoxifen (n=64) 
 
1 
0.74 (0.53 – 1.02) 
 
0.067 
ER Positive   
Overall follow-up (events: n=187) 
Placebo (n=108) 
Tamoxifen (n=79) 
 
1 
0.72 (0.54 – 0.97) 
 
0.028 
During treatment period (events: n=75) 
Placebo (n=42) 
Tamoxifen (n=33) 
 
1 
0.78 (0.50 – 1.23) 
 
0.290 
Post treatment period (events: n=112) 
Placebo (n=66) 
Tamoxifen (n=46) 
 
1 
0.68 (0.47 – 0.996) 
 
0.048 
 
B 
 
 
   
Patients with IHC data HR (95% CI) Cox  
(p-value) 
Overall follow-up (n=179) 
Placebo (n=100) 
Tamoxifen (n=79) 
 
1 
0.78 (0.58 – 1.05) 
 
0.100 
ER positives (n=139) 
Placebo (n=85) 
Tamoxifen (n=54) 
 
1 
0.63 (0.45 – 0.88) 
 
0.007 
ER negative (events: n=40) 
Placebo (n=15) 
Tamoxifen (n=25) 
 
1 
1.65 (0.87 – 3.12) 
 
0.127 
 18 
 
 
 
Table 2 
 
Major Demographics of the IHC sample set 
 
 Tamoxifen Placebo 
Number of patients 79 100 
   
Age: median (range) 48 yrs (37 – 67) 49 yrs (30 – 67) 
HRT (n,%) 17 (21) 21 (21) 
Size: median (range) 15mm (4 – 50) 15mm (2 – 60) 
Grade (n,%): 
 I 
 II 
 III 
 Others*  
 
13 (16) 
24 (30) 
23 (29) 
19 (25) 
 
16 (16) 
35 (35) 
30 (30) 
19 (19) 
Nodal Status (n,%): 
 Positive 
 Negative/ Unknown 
 
22 (28) 
77 (72) 
 
22 (22) 
78 (78) 
   
Follow-up time   
0-8 years 40 44 
> 8 years 39 56 
   
ER +ve cases   
ALL 54 85 
0-8 years 29 37 
>8 years 25 48 
   
ER -ve cases   
ALL 25 15 
0-8 years 11   7 
>8 years 14   8 
* Others – unknown, MOD, poor, well, not assessable 
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Table 3:  
Comparison of biomarker expression between placebo and tamoxifen groups in 
overall follow-up period 
 
Parameter  Tamoxifen (n=79) Placebo (n=100) p-value 
ER 
Median H-score 
(IQR) 
86.4 (0 – 163.9) 150.8 (73.6 – 184.6) 0.001 
ER+ Median H-score 
(IQR) 
135.8 (84.0 – 182.2) 164 (110.6 – 191.4 0.053 
   Status    +ve 54 (68%) 85 (85%)   
                  -ve 25 (32%) 15 (15%) 0.008 
          
PgR 
Median H-score 
(IQR) 
52.9 (0 – 153.7) 87.2 (1.3 – 168.4) 0.180 
  
Median H-score 
(IQR) 
110.7 (58.8 – 184.5) 115.9 (66.9 – 180.6) 0.643 
   Status    +ve 50 (63%) 76 (76%)   
                  -ve 29 (37%) 24 (24%) 0.064 
     
ER/PgR ER + PgR + 49 (62%) 76 (76%)   
0.800* 
  status ER + PgR - 5 (6%) 9 (9%) 
  ER - PgR - 24 (30%) 15 (15%)  
  ER - PgR +  1 (1%) 0    
          
Ki67 
Median % +ve 
(IQR) 
10.2 (5.1 – 34.5) 10.2 (4.2 – 18.3) 0.280 
          
HER2  Status     +ve 12 (15%) 10 (10%)   
                   -ve 67 (85%) 90 (90%) 0.294 
          
EGFR  Status     +ve 15 (19%) 12 (12%)   
                   -ve 64 (81%) 88 (88%) 0.205 
* P-value relates to the difference between PgR+ and PgR- among the ER+ by 
chi-square test.  
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Table 4:  
Comparison of biomarker expression between placebo and tamoxifen groups 
in on-treatment and post-treatment follow-up periods  
 
 
 
 
 
 
 
 
  
  
 
 
 Years 0-8, on treatment Years >8, post-treatment 
Parameter     Tamoxifen Placebo 
P-
value 
Tamoxifen Placebo 
P-
value 
    N 40 44   39 56  
             
ER 
       
All 
Median H-
score (IQR) 
83.0 
(0 – 151.9) 
118.9 
(30.7 – 181.2) 
0.043 
107.5 
(0 – 182.3) 
162.1 
(103.0 – 195.0) 
0.018 
  
      
ER+ 
Median H-
score (IQR) 
104 
(71.2 – 165.0) 
148.5 
(81.1 – 182.7) 
0.148 
162.8 
(110.5 – 191.4) 
169.5 
(134.2 – 196.3) 
0.390 
  All 
 Status            
+ve 
29 (73%) 37 (84%) 
  
25 (64%) 48 (86%)  
    
                        
-ve 
11 (27%) 7 (16%) 0.196 14 (36%) 8 (14%) 0.014 
             
PgR 
All 
Median H-
score (IQR) 
55.2 
(0 – 111.3) 
73.4 
(0.8 – 167.6) 
0.582 
52.9 
(0 – 167.7) 
101.3 
(3.5 – 168.4) 
0.272 
  
PgR
+ 
Median H-
score (IQR) 
92.3 
(52.3 – 172.8) 
96.5 
(67.0 – 180.8) 
0.988 
146 
(90.6 – 187.7) 
121.4 
(59.6 – 180.0) 
0.291 
  
All 
 Status            
+ve 
27 (68%) 32 (73%)   23 (59%) 44 (79%)  
  
  
                        
-ve 
13 (32%) 12 (27%) 0.601 16 (41%) 12 (21%) 0.039 
             
ER/PgR   ER + PgR + 26 32  23 44  
    ER + PgR - 3 5  2 4  
    ER - PgR + 1 0  nil nil  
    ER - PgR - 10 7  14 8  
             
Ki67 
All 
Median % 
+ve (IQR) 
9.9  
(4.7 – 20.4) 
9.1  
(3.3 – 18.3) 
0.660 
10.9 
(5.4 – 47.0) 
10.9 
(4.6 – 18.2) 
0.180 
             
HER2 
All 
 Status            
+ve 
5 (12%) 6 (14%)   7 (18%) 4 (7%)  
  
  
                        
-ve 
35 (88%) 38 (86%) 0.877 32 (82%) 52 (93%) 0.105 
             
EGFR 
All 
 Status            
+ve 
6 (15%) 6 (14%)   9 (23%) 6 (11%)  
  
  
                        
-ve 
34 (85%) 37 (86%) 0.892 30 (77%) 50 (89%) 0.104 
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Supplementary Table 1 Immunohistochemical analysis of biomarkers 
 
 
 
  
 
 
 
 
 
Biomarker Antibody Antigen Retrieval and Scoring Methods 
ER Clone 6F11 Vector 
VP E-614 dilution 1/40 
10 minutes microwaving  
Full power in pre-heated  
citrate buffer pH 6 
 
H Score: % staining positive & intensity.  
Cut-off > 1 
PgR 321 clone Vector Labs VP-P976 
dilution 1/100 
10 minutes microwaving full power in pre-heated 
citrate buffer pH 6 
H Score: % staining positive & intensity.  
Cut-off > 1 
HER2 HercepTest+ K5207 
Dako 
40 minutes 10 mM Epitope retrieval buffer in water 
bath at 95-990C 
0, 1+,2+,3+ positive membrane staining  
Cut-off 3+ is positive 
2+ scores are subjected to FISH analyses 
FISH Fluorescence in situ hybridization of 
HER2 using 
PathVysion Abbott HER-2 neu Kit 
when IHC 2+ cases 
According to Kit instructions. 
HER2 red coloured and C17 centromere green ratio 
(1.8-2.2 borderline) 
EGFR Clone31G7Invitrogen 
clone 31G7 Zymed 
dilution 1/50 
15 minutes in pre-warmed 5% pronase E (Sigma 
P6911) buffer  
% positive membrane staining. Cut-off >0 is +ve 
Ki67 MIB-1 clone Dako (M7240) 
Dilution 1/40 
10 minutes microwaving full power in pre-heated 
citrate buffer pH 6 
% positive nuclei score. No cutoff 
